Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 14/20 | 0.58 |
| ▸ | EGFR | P00533 | 14/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304450 | 0.84 | EGFR (0.58) | FLT1EGFRKDRSYKVCP | |
| SCHEMBL7124392 | 0.84 | EGFR (0.63) | FLT1EGFRKDRSYK | |
| SCHEMBL6309519 | 0.84 | EGFR (0.56) | FLT1EGFRKDRSYKVCP | |
| SCHEMBL6302263 | 0.83 | EGFR (0.57) | FLT1EGFRKDRSYKVCP | |
| SCHEMBL7115466 | 0.83 | FLT1 (0.74) | FLT1EGFRKDR | |
| SCHEMBL6303987 | 0.82 | EGFR (0.56) | FLT1EGFRKDRSYKVCP | |
| SCHEMBL7122707 | 0.82 | EGFR (0.61) | FLT1EGFRKDRSYK | |
| SCHEMBL7124425 | 0.82 | EGFR (0.66) | FLT1EGFRKDRSYK | |
| SCHEMBL7124381 | 0.82 | EGFR (0.71) | FLT1EGFRKDRSYK | |
| SCHEMBL7124535 | 0.81 | FLT1 (0.71) | FLT1EGFRKDRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101328186-A | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2008-12-24 | — | — | CN | disclosed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| CN-1280580-A | Thienopyrimidine and thienopyridine derivatives as anticancer agents | PFIZER PROD INC (US) | 2001-01-17 | — | — | CN | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | FLT1 1043/4885EGFR 2961/4885KDR 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.